Personalized Medicine Pay Off For Pharma, Payers Contrasted In Study

Private payers may have difficulty realizing a positive short term return on investment for covering a targeted breast cancer therapy like Genentech's Herceptin - at least based on individual patient costs, a study by the Deloitte Center for Health Solutions finds